ADMA Biologics ADMA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's stock issuance proceeds?
- ADMA Biologics (ADMA) reported stock issuance proceeds of $588K in Q1 2026.
- How has ADMA Biologics's stock issuance proceeds changed year-over-year?
- ADMA Biologics's stock issuance proceeds increased by 482.2% year-over-year, from $101K to $588K.
- What is the long-term trend for ADMA Biologics's stock issuance proceeds?
- Over 4 years (2021 to 2025), ADMA Biologics's stock issuance proceeds has grown at a -60.4% compound annual growth rate (CAGR), from $121.12M to $2.98M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.